StockMirror — Stock Screener

SOLARA Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Solara Active Pharma Sciences reported its best quarter in 8 quarters (Q4 FY26), with revenue of INR 392 cr (+12% QoQ), gross margin 47% (+170 bps QoQ), and EBITDA of INR 61 cr (+65% QoQ). The base business (ex-ibuprofen) continues to drive performance with 26% EBITDA margins. The ibuprofen business remains a drag with negative EBITDA, and management has appointed bankers to evaluate strategic options (sale or conversion) with decision expected in H1 FY27. The company reduced debt by INR 158 cr in FY26 and targets debt-free status by FY29. R&D is being revived with plans for 4-5 DMF filings per year, though benefits are expected from FY29 onwards. No explicit forward guidance was given, but management expressed confidence in maintaining momentum.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized driving revenue growth through base business expansion (new customers, geographies) while simultaneously improving margins through operational efficiency, yield improvement, and capacity debottlenecking. The target is to deliver sustainable, profitable growth as stated in their

About Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited (SOLARA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More